Baldiness

CAELYX Combo Treatment For Ovarian Cancer Offers Low Incidence of Alopecia

by Bald Man on February 19th, 2007

Perhaps I’m still cleansing my soul for the Britney post; perhaps it’s just a news worthy time in the realm of cancer treatments. Regardless, the results of a phase II clinical trial for ovarian cancer treatment have been released, and the indications are positive.

From the press release:

Schering-Plough Corp. (NYSE: SGP) announced today the publication of a multicentre phase II clinical trial that found treatment with CAELYX(R) (pegylated liposomal doxorubicin hydrochloride), in combination with carboplatin, to be highly effective in patients with ovarian cancer which had been previously treated. This CAELYX combination regimen was well tolerated with patients experiencing a low incidence of alopecia and neurotoxicity. This study is featured in the February issue of the Annals of Oncology.

Standard therapy for recurrent ovarian cancer is a regimen containing paclitaxel and carboplatin. However neurotoxicity is a significant cumulative side effect of taxane containing chemotherapy regimens and therefore there is a need for a non-taxane option. The results of this trial show that the combination of CAELYX and carboplatin are similar to standard therapy and may potentially offer low neurotoxicity rates.

Sounds like good news to me. One of the biggest problems with many existing cancer treatments is neurotoxicity, the cumulative effects of repeated doses on the nervous system. Chemotherapies and radiation therapies can do great benefit, but the lingering effects can ultimately be just as devastating. I’m glad to hear news like the CAELYX study.

Share This

Related Stories

Cancer Treatments Improving - Fewer Side Effects in Sight
Head Shaving Theater
Solo Capecitabine Treats Breast Cancer Without Causing Hair Loss
I’m A Kid Foundation
New Cancer Drug Cocktail May Treat Multiple Myeloma Without Treatment Related Hair Loss

POSTED IN: Bald Medicine